Department of Microbiology and Immunology, The University of Western Ontario, London, ON, Canada.
Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA; Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA.
Antiviral Res. 2021 Apr;188:105034. doi: 10.1016/j.antiviral.2021.105034. Epub 2021 Feb 10.
Human adenoviruses (HAdV) are ubiquitous human pathogens that cause a significant burden of respiratory, ocular, and gastrointestinal illnesses. Although HAdV infections are generally self-limiting, pediatric and immunocompromised individuals are at particular risk for developing severe disease. Currently, no approved antiviral therapies specific to HAdV exist. Recent outbreaks underscore the need for effective antiviral agents to treat life-threatening infections. In this review we will focus on recent developments in search of potential therapeutic agents for controlling HAdV infections, with a focus on those targeting post-entry stages of the virus replicative cycle.
人类腺病毒（HAdV）是普遍存在的人类病原体，可引起呼吸道、眼部和胃肠道疾病，造成巨大负担。尽管 HAdV 感染通常是自限性的，但儿科和免疫功能低下者特别容易发生严重疾病。目前，尚无针对 HAdV 的批准抗病毒疗法。最近的疫情突显了需要有效的抗病毒药物来治疗危及生命的感染。在这篇综述中，我们将重点关注寻找控制 HAdV 感染的潜在治疗药物的最新进展，重点关注针对病毒复制周期进入后阶段的药物。
